Posted by Michael Wonder on 24 Jul 2025
Avidity Biosciences receives FDA breakthrough therapy designation for delpacibart zotadirsen for the treatment of DMD in people with mutations amenable to exon 44 skipping
23 July 2025 - On track for planned BLA submission for delpacibart zotadirsen at year end 2025.
Avidity Biosciences today announced that the US FDA has granted breakthrough therapy designation to delpacibart zotadirsen for the treatment of Duchenne muscular dystrophy in people living with mutations amenable to exon 44 skipping.
Read Avidity Biosciences press release
